I write Time-saving Fundamental analysis that delivers the insights you need to make smarter decisions.
Live Last read · last published · next check
#28 : Part 2 shifts from understanding the business to evaluating the investment. We decode Gufic's growth roadmap, valuation, risks, and what could drive the next phase of value creation.
Follow the journey of cash inside an automobile company and understand how Inventory Days, Debtor Days, Payable Days, and the Cash Conversion Cycle fit together.
#27 : This first part breaks down Gufic's business model, revenue engines, product portfolio and manufacturing capabilities, explaining why complex injectables are far from a commodity business.
#26 : Understanding Sudeep Pharma's business model, specialty ingredients strategy, manufacturing footprint, R&D engine and the competitive advantages driving long-term value creation.
#26 : We'll use a simple notebook business to decode every line of a Profit & Loss Statement, helping you understand how businesses actually make money- not just memorize accounting terms.
#25 : Beyond the promoter story lies the real debate: ABS demand, capacity expansion, Thailand optionality, management execution and whether the market is underestimating the opportunity.
#24 : A founder builds a company, sells it, watches it pass through four global owners and buys it back 25 years later. The promoter story is fascinating—but is that the real investment thesis ?
#22 : The business is changing. The question is whether KOEL remains a beneficiary of India's capex cycle or evolves into a higher-quality industrial compounder. This edition explores that possibility
#22 : KOEL’s financials don’t tell the full story. We break down its three-engine structure, HHP expansion, and NBFC distortion to build the right mental model before the investment thesis.
#22 : India is pushing a ₹37,500 crore coal gasification mission. But where will the real profits emerge — and where is the market getting ahead of reality?
